Eledon Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Eledon Pharmaceuticals, Inc. (ELDN) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.50% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-03-19
- Eledon Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-03-31 was 4.20%.
- Eledon Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.50%, a 7.14% increase from fiscal 2024.
- Eledon Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.20%, a 13.51% increase from fiscal 2023.
- Eledon Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.70%, a 85.00% increase from fiscal 2022.
- Eledon Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 2.00%, a 100.00% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month as first filed |
|---|---|---|---|---|---|---|
| 2025-12-31 | 4.50% 10-K · filed 2026-03-19 | |||||
| 2024-12-31 | 4.20% 10-K · filed 2026-03-19 | |||||
| 2024-09-30 | 3.58% 10-Q · filed 2024-11-12 | |||||
| 2024-06-30 | 4.33% 10-Q · filed 2024-08-19 | |||||
| 2024-03-31 | 4.20% 10-Q/A · filed 2024-08-19 | |||||
| 2023-12-31 | 3.70% 10-K/A · filed 2025-08-14 | |||||
| 2023-04-28 | 3.50% 10-K/A · filed 2024-08-19 | |||||
| 2022-12-31 | 2.00% 10-K/A · filed 2024-08-19 | |||||
| 2021-12-31 | 1.00% 10-K · filed 2023-03-30 | |||||
| 2016-12-31 | 0.95% 10-K · filed 2018-04-02 | 1.52% 10-K · filed 2017-03-03 | ||||
| 2015-12-31 | 1.79% 10-K · filed 2017-03-03 | |||||
| 2014-12-31 | 1.83% 10-K · filed 2017-03-03 | |||||
| 2013-12-31 | 1.72% 10-K · filed 2016-03-10 | |||||
| 2012-12-31 | 0.79% 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |